In human prostate cancer cells, 6-Shogaol (40 μmol/L) treatment of prostate cancer PC-3, DU145 and LNCaP cells reduced the levels of TNF-α-induced p-NF-kBp65ser536 and the negative regulator p-IKBαS32/36. Here, TNF is linked to prostate carcinoma.